#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Hepatitis E: what we need to know about this dis ease?


Authors: H. Slepčanová 1,2;  L. Petroušová 3,4
Authors‘ workplace: Ústav laboratorní medicíny, Lékařská fakulta OU a FN Ostrava 1;  Ústav mikrobiologie, Lékařská fakulta a Přírodovědecká fakulta UP v Olomouci 2;  Klinika infekčního lékařství, FN Ostrava 3;  Katedra interních oborů, Lékařská fakulta OU, Ostrava 4
Published in: Gastroent Hepatol 2024; 78(5): 424-430
Category:
doi: https://doi.org/10.48095/ccgh2024424

Overview

The hepatitis E virus (HEV) represents a significant global health concern, accounting for the second-highest incidence of viral hepatitis. Eight genotypes of HEV have been identified, four of which are associated with disease in humans. Genotypes 1 and 2 are transmitted via contaminated water, whereas genotypes 3 and 4 are zoonotic and transmitted through the consumption of undercooked meat, particularly pork, venison, and rabbit. Genotype 3 is endemic in the Czech Republic, with reservoirs in pigs, wild game, and rabbits. A hepatitis E virus (HEV) infection presents with symptoms similar to those observed in other types of hepatitis, including fatigue, fever, malaise, jaundice, and dark urine. In immunocompetent patients, the infection typically resolves spontaneously. However, in immunocompromised patients, it can progress to a chronic state, leading to cirrhosis and liver failure. The presence of preexisting liver disease is a significant factor in the context of HEV, as patients with chronic liver disease infected with HEV are at an elevated risk of liver failure, which can potentially result in death. A diagnosis is made by detecting immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies to the hepatitis E virus (HEV) and HEV ribonucleic acid (RNA) in blood and stool samples. The recommended diagnostic procedures are contingent upon the patient‘s immune status and epidemiological context. In most cases, treatment is not necessary; however, ribavirin and interferon a are employed in severe instances. Prevention strategies encompass enhanced hygiene practices, thorough cooking of meat, and in developing countries, the consideration of vaccination. The vaccine Hecolin® is available in China and is efficacious against genotypes 1, 2, and 4; however, it is not yet registered in the European Union.

Keywords:

hepatitis E – hepatitis E virus – genotypes – transmission – Czech Republic


Sources
1. World Health Organization. Hepatitis E: Fact sheet. 2023 [online]. Dostupné z: https: //www.who.int/en/news-room/fact-sheets/detail/hepatitis-e.
2. Yin X, Feng Z. Hepatitis E Virus Entry. Viruses 2019; 11 (10): 883. doi: 10.3390/v11100883.
3. Purdy MA, Drexler JF, Meng XJ et al. ICTV Virus Taxonomy Profile: Hepeviridae 2022. J Gen Virol 2022; 103 (9). doi: 10.1099/jgv.0.001778.
4. Corman VM, Nagy P, Ostermann S et al. Hepatitis E Virus Genotype 7 RNA and Antibody Kinetics in Naturally Infected Dromedary Calves, United Arab Emirates. Emerg Infect Dis 2020; 26 (9): 2214–2217. doi: 10.3201/eid2609. 191758.
5. La Rosa G, Pourshaban M, Iaconelli M et al. Molecular detection of hepatitis E virus in sewage samples. Appl Environ Microbiol 2010; 76 (17): 5870–5873. doi: 10.1128/AEM.00336-10.
6. Strakova P, Kubankova M, Vasickova P et al. Hepatitis E virus in archived sera from wild boars (Sus scrofa), Czech Republic. Transbound Emerg Dis 2018; 65 (6): 1770–1774. doi: 10.1111/ tbed.12950.
7. Khuroo MS, Kamili S a Khuroo MS. Clinical course and duration of viremia in vertically transmitted hepatitis E virus (HEV) infection in babies born to HEV–infected mothers. J Viral Hepat 2009; 16 (7): 519–523. doi: 10.1111/j.1365- 2893.2009.01101.x.
8. Němeček V, Butovičová P, Malý M et al. Prevalence protilátek proti viru hepatitidy E v České republice – sérologický přehled. Epidemiol Mikrobiol Imunol 2017; 66 (1): 3–7.
9. Státní zdravotní ústav. Výskyt vybraných hlášených infekcí podle věkových skupin v České republice v letech 2013–2023. 2024 [online]. Dostupné z: https: //szu.cz/publikace-szu/data/ infekce-v-cr/.
10. Kieslichova E. Transplantace jater pro akutní selhání jater. Gastroent Hepatol 2024; 78 (2): 95–100. doi: 10.48095/ccgh202495.
11. Kumar A a Saraswat VA. Hepatitis E and Acute-on-Chronic Liver Failure. J Clin Exp Hepatol 2013; 3 (3): 225–230. doi: 10.1016/j.jceh. 2013.08.013.
12. Mihalčin M, Husova L, Vasickova P et al. Hepatitis E – epidemiology and clinical course in the largest cohort in the Czech Republic. Arch Med Sci 2022; 18 (5): 1395–1398. doi: 10.5114/ aoms/152338.
13. Kamar N, Selves J, Mansuy JM et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358 (8): 811–817. doi: 10.1056/NEJMoa0706992.
14. Aggarwal A, Perumpail RB, Tummala S et al. Hepatitis E virus infection in the liver transplant recipients: Clinical presentation and management. Word J Hepatol 2016; 8 (2): 117–122. doi: 10.4254/wjh.v8.i2.117.
15. Jilani N, Das BC, Husain SA et al. Hepatitis E virus infection and fulminant hepatic failure during pregnancy. J Gastroenterol Hepatol 2007; 22 (5): 676–682. doi: 10.1111/ j.1440-1746.2007.04913.x.
16. Horvatits T a Pischke S. HEV in pregnancy: Understanding the crucial role of steroid hormones. Liver Int 2019; 39 (4): 621–622. doi: 10.1111/liv.13942.
17. Abravanel F, Pique J, Couturier E et al. Acute hepatitis E in French patients and neurological manifestations. J Infect 2018; 77 (3): 220–226. doi: 10.1016/j.jinf.2018.06.007.
18. Sekula J a Paraličová Z. Analýza pacientov s akútnou hepatitídou E na Klinike infektológie a cestovnej medicíny v Košiciach. Epidemiol Mikrobiol Imunol 2024; 73 (2): 106–111. doi: 10.61568/emi/11-6306/20240424/137 083.
19. Dalton HR, Kamar N, Baylis SA et al. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol 2018; 68 (6): 1256–1271. doi: 10.1016/j.jhep.2018.03.005.
20. Zhang J, Zhang XF, Huang SJ et al. Long-term efficacy of a hepatitis E vaccine. N Engl J Med 2015; 372 (10): 914–922. doi: 10.1056/ NEJMoa1406011.
21. Li Y, Huang X, Zhang Z et al. Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation. Viruses 2020; 12 (1): 109. doi: 10.3390/v12010109.
22. Kamar N, Abravanel F, Behrendt P et al. Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. Clin Infect Dis 2020; 71 (5): 1204–1211. doi: 10.1093/cid/ ciz953.
ORCID autorek
H. Slepčanová 0009-0008-2641-200X,
L. Petroušová 0000-0002-8769-9517.
Doručeno/Submitted: 12. 8. 2024
Přijato/Accepted: 16. 9. 2024
Korespondenční autorka
Mgr. Hana Slepčanová
Ústav laboratorní medicíny
LF OU a FN Ostrava
17. listopadu 1790/5
708 52 Ostrava-Poruba
hana.slepcanova@fno.cz
Labels
Paediatric gastroenterology Gastroenterology and hepatology Surgery
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#